 | Up a level |
Hoeper, Marius M., McLaughlin, Vallerie V., Albert Barbera, Joan, Frost, Adaani E., Ghofrani, Hossein-Ardeschir, Peacock, Andrew J., Simonneau, Gerald, Rosenkranz, Stephan, Oudiz, Ronald J., White, R. James, Miller, Karen L., Langley, Jonathan, Harris, Julia H. N., Blair, Christiana, Rubin, Lewis J. and Vachiery, Jean-Luc (2016). Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Resp. Med., 4 (11). S. 894 - 902. OXFORD: ELSEVIER SCI LTD. ISSN 2213-2600
McLaughlin, Vallerie V., Vachiery, Jean-Luc, Oudiz, Ronald J., Rosenkranz, Stephan, Galie, Nazzareno, Barbera, Joan A., Frost, Adaani E., Ghofrani, Hossein-Ardeschir, Peacock, Andrew J., Simonneau, Gerald, Rubin, Lewis J., Blair, Christiana, Langley, Jonathan and Hoeper, Marius M. (2019). Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J. Heart Lung Transplant., 38 (12). S. 1286 - 1296. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1557-3117
Rosenkranz, Stephan, Channick, Richard, Chin, Kelly M., Jenner, Bartosz, Gaine, Sean, Galie, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., McLaughlin, Vallerie V., Du Roure, Camille, Rubin, Lewis J., Sitbon, Olivier, Tapson, Victor and Lang, Irene M. . The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur. J. Heart Fail.. HOBOKEN: WILEY. ISSN 1879-0844